Medifast Q3 2026 slides: productivity surge offsets coach decline
Medifast (MED) reported Q3 2026 revenue of $72M, an adjusted loss of $0.19/share, and a 6.23% premarket stock rise. Despite a 47.7% drop in active coaches, revenue per coach surged 54% to $7,064. The company is pivoting to metabolic health under the Trilivy brand, with $173M in cash and investments.
How this was made
The 30-second read
Why it matters
The earnings beat and strong cash position support a near‑term price rally, but ongoing revenue contraction and restructuring costs temper the outlook.
Market read
First‑time disclosure of Q3 2026 results; earnings beat drives immediate market reaction.
What to watch
Restructuring charges of $15.4 M and a 19.4% YoY revenue drop may pressure margins if coach productivity gains plateau.
Background
Medifast presented its Q3 2026 earnings supplement, highlighting a brand shift to Trilivy and a productivity surge among remaining coaches.
Ticker impact
Q3 2026 earnings supplement disclosed a loss of $0.19 per share versus a $0.62 consensus loss, with revenue of $72 M beating estimates; shares rose 6.2% pre‑market.
likely upward pressure as the market prices in the earnings beat and improved coach productivity.
The surprise loss beat and pre‑market price jump indicate immediate buying interest; the guidance range was met and cash position remains strong.
Market effects
Weight‑loss/metabolic‑health sector may see renewed investor interest as Medifast demonstrates a viable turnaround model.
U.S. small‑cap health‑and‑wellness stocks could experience modest spillover buying.
Limited; the story is primarily U.S. focused.
Counterpoint
The revenue decline and widening operating loss suggest the turnaround may be fragile; investors could be over‑optimistic on short‑term price moves.
Key entities
- companyMedifast
U.S. weight‑loss and metabolic‑health company (NYSE:MED).
